🇺🇸 FDA
Patent

US 8268776

Macrocylic oximyl hepatitis C protease inhibitors

granted A61PA61P31/12

Quick answer

US patent 8268776 (Macrocylic oximyl hepatitis C protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61P, A61P31/12